The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison”

In this exploratory analysis of 660 men with newly diagnosed metastatic prostate cancer randomised within a clinical trial, a low automated bone scan index was found to be predictive of overall and failure-free survival benefit from the addition of prostate radiotherapy to standard of care systemic therapy. This was also observed with secondary clinical end points.